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The risk of having a baby with a neural tube defect
(NTD) for women taking sodium valproate (VPA) is
about 2%1, or at least 60 times the background risk
in the UK. Since this is similar to that for recurrence
of a NTD in someone who has previously had a baby
with this condition, for whom high-dose periconceptual
folic acid (4 mgs/day) is known to offer considerable
protection2, it has been suggested that women on VPA
should take a similar high-dose periconceptually. We
report the case of a woman exposed to VPA who gave
birth to an infant with an NTD, among other malforma-
tions, despite taking high-dose folic acid periconceptu-
ally and emphasize there is no evidence that folic acid
in any dose protects against NTDs caused by VPA.
Case Report
A baby boy was delivered to a 26 year old woman
following a planned pregnancy. The child had a lum-
bosacral NTD, small ventricular and atrial septal de-
fects, a cleft of the soft palate, bilateral talipes and fea-
tures consistent with foetal valproate syndrome. Chro-
mosomal analysis demonstrated a normal male kary-
otype. The NTD and cleft palate were subsequently
repaired.1059–1311/99/040253 + 02 $12.00/0The mother, who was otherwise well, had presented
aged 16 years with a 2 year history of prolonged ab-
sence seizures and an EEG showing features in keeping
with primary generalized epilepsy. She was prescribed
VPA 500 mg BD (twice daily) and became seizure free.
Four years later the seizures returned and the dose of
VPA was increased to 1000 mgs twice daily. The mar-
ried woman, who at the age of 23 had been seizure
free for 4 years, was prescribed 4mg/day folic acid.
She remained seizure free and 18 months later became
pregnant. She stopped the folic acid at the end of the
first trimester. There was no family history of birth
abnormalities. Foetal ultrasound during the pregnancy
had raised no concerns.
Discussion
Sodium valproate was the probable cause of the mal-
formations, as all have been described with this drug3,
the NTD was in the typical site for VPA4, and the child
had features of foetal valproate syndrome. A NTD has
not, to our knowledge, previously been described in
an infant born to a woman on VPA while taking peri-
conceptual folic acid and implies that folic acid either
provides incomplete protection against NTDs caused
by VPA or may not work at all. Experimental evidence
suggests both; in humans the neural tube is thought toc© 1999 BEA Trading Ltd
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1257–1261.close at five or more sites4. Folic acid appears to influ-
ence closure of these differentially, having the greatest
effect on sites one and two corresponding to lumbar
and anencephalic defects, respectively4. Lumbosacral
defects corresponding to site five are the commonest
area of abnormality associated with VPA4. There is
no consistent evidence from animal studies that sup-
plementation with folate or its derivatives reduces the
rate of valproate-induced NTDs5–8. VPA also reduces
serum folate levels in humans to a much lesser extent
than other AEDs, which are less often associated with
NTDs9, 10.
It has been postulated that folic acid prevents be-
tween 50 and 70% of all NTDs11–13. None of the studies
on which these figures are based have investigated the
protective role of folic acid supplementation in women
exposed to VPA. To determine if this is the case would
require a controlled trial. Although unethical to include
a placebo group, since low-dose (0.4 mgs/day) pericon-
ceptual folic acid reduces the background incidence of
NTDs14, it would be possible to compare the effects of
low- and high-dose folic acid. Until firmer evidence is
available, women taking VPA should continue to take
folic acid before and during pregnancy for the same
reasons as those women not on VPA. Doctors should
not be reassured that infants exposed to VPA in utero
will not develop NTDs and should monitor such preg-
nancies with appropriate use of alpha fetoprotein blood
sampling, foetal ultrasound and amniocentesis.References
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